Sector Analysis · 6 min read · 2026-04-02
The 9 indicators of a biotech binary setup.
Biotech binary events are not random. Nine signals separate the high-conviction setups from the gambles.
Most biotech binaries are coin-flips priced like coin-flips.
FDA approval decisions and Phase 3 trial readouts produce same-day stock moves of 40 to 80 percent. The base-rate FDA approval probability for a Phase 3-completed drug is approximately 60 percent. The signals separate the genuinely high-probability events from the consensus 50/50s.
The nine indicators
The nine indicators of binary-event quality.
Each is in clinical-trial registries, FDA briefing documents, or company filings. Combined, they shift the conditional probability above or below the base rate.
Phase 2 data magnitude relative to comparators
Threshold: clearly differentiated
Phase 3 success rates correlate strongly with Phase 2 effect size. Marginally positive Phase 2 data has lower replication probability.
Prior FDA approvals in same mechanism class
Pattern: precedent vs. first-in-class
Mechanism-class precedent improves approval odds. First-in-class drugs face higher bars on benefit-risk.
Trial design rigor and endpoints
Pattern: pre-specified primary
Pre-specified primary endpoints with adequate power are more credible. Post-hoc subgroup analyses are warning.
Adcom (Advisory Committee) recommendation
Pattern: recommended approval
Adcom recommendations precede most FDA decisions and predict outcome 80%+ of the time. The vote tally is informative.
Cash runway through and beyond decision
Threshold: > 12 months runway
Companies entering binary events with insufficient cash face dilution if results are mixed. Adequate runway protects the holder.
Options skew widening into the event
Pattern: extreme implied vol
Pre-event implied vol pricing extreme moves indicates institutional positioning. Sometimes informative, sometimes contrarian.
Insider buying or holding pre-event
Form 4 pattern
Insider buying ahead of a binary event signals confidence. Insider selling ahead is the opposite signal.
Manufacturing inspection status
Source: FDA EIR
FDA-required manufacturing facility inspections must be passed for approval. Inspection issues are common deal-killers separate from clinical data.
Comparator trial data and competitive landscape
Pattern: clean differentiation
Drugs facing direct head-to-head comparators with strong data face higher bars. Niche or differentiated indications produce cleaner approvals.
What a biotech binary event is
Biotech stocks experience 'binary events' — FDA decisions, Phase 3 trial readouts, advisory committee meetings — where the stock moves 30 percent or more in a single session. The events are scheduled (PDUFA dates, ADCOM dates) or unscheduled (interim trial readouts). The asymmetry of the move makes biotech a high-stakes special-situations sector for traders willing to do the work.
The base-rate statistics are well-established. Phase 3 trial success rates for U.S.-conducted oncology trials run approximately 35 percent; for cardiovascular, 50 percent; for infectious disease, 65 percent. FDA approval rates for drugs that complete Phase 3 are approximately 60 percent across all therapeutic areas. The signals shift the conditional probability.
Phase 2 data is the strongest predictor of Phase 3 success
Drugs with strong Phase 2 effect sizes — clean separation from placebo, dose-response relationship, biological plausibility — succeed in Phase 3 at materially higher rates than drugs with marginal Phase 2 data. The mechanism is not surprising: large effects are more likely to replicate.
The discipline is to read the Phase 2 publication rather than the company's framing of it. Phase 2 publications are typically peer-reviewed and contain the methodological detail required to assess effect-size magnitude and design rigor. Marginal Phase 2 data presented enthusiastically by management is a common warning.
Adcoms — the public preview
FDA Advisory Committees meet publicly and vote non-binding recommendations on approval. The vote is published the same day as the meeting. FDA approval decisions follow Adcom recommendations approximately 80 percent of the time. The Adcom is therefore a high-information event that often resolves much of the binary risk before the formal PDUFA date.
The Adcom briefing documents — released approximately 48 hours before the meeting — contain the FDA reviewer's analysis. These documents are technical, written for committee members, and rarely read by retail. Reading them is the highest-leverage research activity for a biotech trader.
Position sizing the binary
Biotech binary trades require small position sizes (0.5–2 percent per name) and broad diversification (8–15 names per cycle). The strategy depends on positive expected value across many trades, not on any single bet. Concentrated bets on individual binaries have wiped out otherwise sound portfolios.
Options can structure the trade more conservatively. Buying calls with controlled cost or constructing risk-defined spreads (call spreads, butterflies) caps the loss at the premium paid. The trade-off is that option pricing already reflects the binary; the structures are not free.
Get the nine, every Monday.
Free weekly digest. The only U.S. equity letter that publishes a name only when nine independent signals align.
Common questions
Questions.
Where do I find PDUFA dates?
The FDA publishes PDUFA dates upon NDA acceptance. Biopharma Catalyst, Endpoints News, and Pink Sheets aggregate calendars. Free tier coverage is adequate for retail.
Are biotech ETFs safer than picking names?
ETFs (XBI, IBB) diversify single-name binary risk but capture the sector's beta to interest rates and risk appetite. Different exposures, both have roles.
What's the historical FDA approval rate?
Approximately 88% on first cycle for drugs that reach the FDA's review with full Phase 3 support. The lower rate (~60%) at Phase 3 completion includes drugs that don't proceed to filing.
Can I short biotech binaries?
Yes via puts, but premiums are high. Short-stock positions require borrow that is sometimes expensive. The strategy is structurally challenging for retail.
Does insider trading occur ahead of these events?
Heavily regulated. Insider transactions in the 30 days before a binary are often subject to 10b5-1 plan restrictions. Allegations of leakage are investigated by the SEC.
How predictive are Adcom votes?
FDA approval follows the Adcom vote approximately 80% of the time. Discrepancies happen — FDA can approve over an Adcom 'no' or reject after an Adcom 'yes' — but the vote is informative.
One name. Sometimes weeks of silence. Always with conviction.
Free weekly digest. No credit card. Unsubscribe anytime.